Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration

The clinical utility of stimulator of interferon genes (STING) agonists has been limited due to poor tumour-targeting and unwanted toxicity following systemic delivery. Here we describe a robust tumour-targeted STING agonist, ZnCDA, formed by the encapsulation of bacterial-derived cyclic dimeric adenosine monophosphate (CDA) in nanoscale coordination polymers. Intravenously injected ZnCDA prolongs CDA circulation and efficiently targets tumours, mediating robust anti-tumour effects in a diverse set of preclinical cancer models at a single dose. Our findings reveal that ZnCDA enhances tumour accumulation by disrupting endothelial cells in the tumour vasculature. ZnCDA preferentially targets tumour-associated macrophages to modulate antigen processing and presentation and subsequent priming of an anti-tumour T-cell response. ZnCDA reinvigorates the anti-tumour activity of both radiotherapy and immune checkpoint inhibitors in immunologically 'cold' pancreatic and glioma tumour models, offering a promising combination strategy for the treatment of intractable human cancers. Activation of the stimulator of interferon genes (STING) can induce immunity in various cancer therapies, but delivery of STING agonists to tumours is challenging. Now a metal-based polymeric nanoparticle delivers STING agonists to tumours upon disruption of endothelial cells in tumour vasculature and targets tumour-associated macrophages, eliciting anti-tumour immune response in hard-to-treat cancer models.

Automated summary

Researchers have developed a metal-based polymeric nanoparticle that delivers STING agonists to tumors, disrupting endothelial cells in the tumor vasculature and targeting tumor-associated macrophages to elicit an anti-tumor immune response in hard-to-treat cancer models.